Nabi Biopharmaceuticals Announces Receipt of $5 Million Milestone Payment

Nabi Biopharmaceuticals NABI has received a $5 million payment from Fresenius USA Manufacturing, Inc. that was triggered by the first commercial sale of Phoslyra, a milestone under the agreement governing the Company's 2006 sale of PhosLo and related assets to Fresenius. These assets included the rights to a new liquid formulation of PhosLo that Fresenius has commercialized as Phoslyra.